MLH3 and lung cancer: We detected that YLAPs and patients diagnosed older than 50 years harbored similar numbers of somatic mutations per tumor, although the tumor mutational burden has been suggested to be increased with age across cancer types in some studies.16 Meanwhile, five pathogenic germline variants in four genes (including well‐studied lung cancer associated genes TP53 and MLH3) showed fundamentally higher occurrence frequencies in YLAPs in comparison with the unclassified EAS population, but none of these variants has been detected in the older group patients.